

## Pharmacy Formulary Updates for March 2019

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status March 2019:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Together ACO- MA
<b>Mulpleta</b>	\$3.65;PA;SP
<b>Pifeltro</b>	\$3.65
<b>Lorbrena</b>	\$3.65;PA;SP
<b>Jivi</b>	MB/RX;SP
<b>Inveltys</b>	\$3.65;PA
<b>Xyosted</b>	\$3.65;PA
<b>Bryhali</b>	\$3.65;PA
<b>Benzoyl Peroxide 4% wash</b>	\$3.65
<b>Promacta powder</b>	\$3.65;SP
<b>Talzenna</b>	\$3.65;PA;SP
<b>Vizimpro</b>	\$3.65;PA;SP
<b>Aripiprazole Tabs</b>	\$3.65;QL;PBHMI/Polypharmacy
<b>Toremifene Citrate</b>	\$3.65
<b>Trelstar</b>	MB/RX;SP

**Key**

**MB:** Medical Benefit

**NC:** Not covered

**NTM:** New-to-market

**PA:** Prior Authorization

**QL:** Quantity Limitation

**SP:** Specialty Pharmacy - provided through CVS/specialty

**ST:** Step Therapy

**MB/RX:** Drug can be dispensed through Medical Benefit or Prescription Benefit